Literature DB >> 12045175

Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs.

Kaori Shinagawa1, Yan-Fen Shi, Jean-Claude Tardif, Tack-Ki Leung, Stanley Nattel.   

Abstract

BACKGROUND: Clinical atrial fibrillation (AF) often results from pathologies that cause atrial structural remodeling. The reversibility of arrhythmogenic structural remodeling on removal of the underlying stimulus has not been studied systematically. METHODS AND
RESULTS: Chronically instrumented dogs were subjected to 4 to 6 weeks of ventricular tachypacing (VTP; 220 to 240 bpm) to induce congestive heart failure (CHF), followed by a 5-week recovery period leading to hemodynamic normalization at 5-week recovery (Wk5(rec)). The duration of burst pacing-induced AF under ketamine/diazepam/isoflurane anesthesia increased progressively during VTP and recovered toward baseline during the recovery period, paralleling changes in atrial dimensions. However, even at full recovery, sustained AF could still be induced under relatively vagotonic morphine/chloralose anesthesia. Wk5(rec) dogs showed no recovery of CHF-induced atrial fibrosis (3.1+/-0.3% for controls versus 10.7+/-1.0% for CHF and 12.0+/-0.8% for Wk5(rec) dogs) or local conduction abnormalities (conduction heterogeneity index 1.8+/-0.1 in controls versus 2.3+/-0.1 in CHF and 2.2+/-0.2 in Wk5(rec) dogs). One week of atrial tachypacing failed to affect the right atrial effective refractory period significantly in CHF dogs but caused highly significant effective refractory period reductions and atrial vulnerability increases in Wk5(rec) dogs.
CONCLUSIONS: Reversal of CHF is followed by normalized atrial function and decreased duration of AF; however, fibrosis and conduction abnormalities are not reversible, and a substrate that can support prolonged AF remains. Early intervention to prevent fixed structural abnormalities may be important in patients with conditions that predispose to the arrhythmia.

Entities:  

Mesh:

Year:  2002        PMID: 12045175     DOI: 10.1161/01.cir.0000016826.62813.f5

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

Review 1.  Proteomics and transcriptomics in atrial fibrillation.

Authors:  Marc Sühling; Carmen Wolke; Christian Scharf; Uwe Lendeckel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-09

Review 2.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

3.  Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling.

Authors:  Thomas H Everett; Emily E Wilson; Sander Verheule; Jose M Guerra; Scott Foreman; Jeffrey E Olgin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-07-28       Impact factor: 4.733

4.  Chronic heart failure and the substrate for atrial fibrillation.

Authors:  Arun Sridhar; Yoshinori Nishijima; Dmitry Terentyev; Mahmood Khan; Radmila Terentyeva; Robert L Hamlin; Tomohiro Nakayama; Sandor Gyorke; Arturo J Cardounel; Cynthia A Carnes
Journal:  Cardiovasc Res       Date:  2009-06-30       Impact factor: 10.787

Review 5.  Transient receptor potential (TRP) channels and cardiac fibrosis.

Authors:  Zhichao Yue; Yanhui Zhang; Jia Xie; Jianmin Jiang; Lixia Yue
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 6.  Biatrial, 3-Dimensional Mapping of Human Atrial Fibrillation: Methodology and Clinical Observations.

Authors:  Nicholas D Skadsberg; Rangadham Nagarakanti; Sanjeev Saksena
Journal:  J Atr Fibrillation       Date:  2009-04-01

7.  Remodeling of atrial ATP-sensitive K⁺ channels in a model of salt-induced elevated blood pressure.

Authors:  Joshua M Lader; Carolina Vasquez; Li Bao; Karen Maass; Jiaxiang Qu; Eirini Kefalogianni; Glenn I Fishman; William A Coetzee; Gregory E Morley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-01       Impact factor: 4.733

Review 8.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000

9.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

10.  Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1.

Authors:  Sander Verheule; Toshiaki Sato; Thomas Everett; Steven K Engle; Dan Otten; Michael Rubart-von der Lohe; Hisako O Nakajima; Hidehiro Nakajima; Loren J Field; Jeffrey E Olgin
Journal:  Circ Res       Date:  2004-04-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.